Kiniksa Pharmaceuticals International, plc $KNSA Holdings Raised by AQR Capital Management LLC

Key Points

• AQR Capital Management LLC has increased its stake in Kiniksa Pharmaceuticals International by 149.1%, owning approximately $10.92 million in KNSA shares as of the end of the first quarter.
• Several institutional investors have significantly modified their holdings, with Deutsche Bank AG increasing its position by 177.1%, now owning shares valued at $8.76 million.
• Kiniksa Pharmaceuticals announced strong quarterly earnings, reporting $0.23 EPS, surpassing estimates and achieving revenue of $156.8 million during the last quarter.

AQR Capital Management LLC grew its stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 149.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 491,761 shares of the company's stock after acquiring an additional 294,319 shares during the quarter. AQR Capital Management LLC owned about 0.67% of Kiniksa Pharmaceuticals International worth $10,922,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of KNSA. Nuveen LLC acquired a new position in Kiniksa Pharmaceuticals International during the first quarter worth approximately $16,992,000. Millennium Management LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 50.9% during the 4th quarter. Millennium Management LLC now owns 779,672 shares of the company's stock valued at $15,422,000 after buying an additional 263,146 shares during the period. Deutsche Bank AG increased its holdings in shares of Kiniksa Pharmaceuticals International by 177.1% during the 1st quarter. Deutsche Bank AG now owns 394,522 shares of the company's stock worth $8,762,000 after buying an additional 252,125 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter worth $4,663,000. Finally, Kodai Capital Management LP purchased a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter worth $4,117,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ:KNSA traded down $0.79 during trading on Tuesday, hitting $35.77. The company's stock had a trading volume of 274,228 shares, compared to its average volume of 400,652. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $17.82 and a fifty-two week high of $37.34. The stock's 50-day moving average price is $32.20 and its two-hundred day moving average price is $27.35. The company has a market capitalization of $2.65 billion, a PE ratio of 894.47 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The firm had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, equities analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on KNSA shares. Wells Fargo & Company boosted their price objective on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 9th. Jefferies Financial Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Sunday, September 7th. Finally, Wedbush reissued an "outperform" rating and issued a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $41.17.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, COO Eben Tessari sold 13,389 shares of the company's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $35.66, for a total value of $477,451.74. Following the sale, the chief operating officer directly owned 44,452 shares of the company's stock, valued at $1,585,158.32. This represents a 23.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Ross Moat sold 3,523 shares of the firm's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $35.31, for a total transaction of $124,397.13. Following the transaction, the insider directly owned 9,415 shares of the company's stock, valued at approximately $332,443.65. This represents a 27.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 544,971 shares of company stock valued at $18,227,065. Corporate insiders own 53.48% of the company's stock.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.